Neuromuscular Junction Diseases

Diseases of the neuromuscular junction cause skeletal muscle fatigue and include inherited and acquired disorders that affect presynaptic, intrasynaptic or postsynaptic components. Discover the latest research on neuromuscular junction diseases here.

January 6, 2021
Preprint
Open Access

Timing and localization of myasthenia gravis-related gene expression

BioRxiv : the Preprint Server for Biology
D. L. E. VergoossenMaartje G. Huijbers
January 16, 2021
Case Report
Open Access

Immunotherapy Induced Myasthenic-Like Syndrome in a Metastatic Melanoma Patient With Amyotrophic Lateral Sclerosis

Clinical Medicine Insights. Oncology
Muhammad JafferSepideh Mokhtari
January 12, 2021

Ythdf is a N6-methyladenosine reader that modulates Fmr1 target mRNA selection and restricts axonal growth in Drosophila

The EMBO Journal
Lina WorpenbergJean-Yves Roignant
December 31, 2020
Comment / Editorial
Open Access

Prognosis in Pediatric Myasthenia Gravis

Pediatric Neurology Briefs
Jena Krueger
January 8, 2021
Open Access

Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease

Cerebellum & Ataxias
Eleonora LauricellaFrancesco Girolamo
January 19, 2021

Giant cell myositis and myocarditis revisited

Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology
Piraye Oflazer
January 6, 2021

Subclinical myasthenia gravis in thymomas

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Florit MarcuseMarc De Baets
January 5, 2021
Open Access

Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses

Frontiers in Immunology
Christoph RuschilMarkus C Kowarik
December 31, 2020
Review
Open Access

How to Build and to Protect the Neuromuscular Junction: The Role of the Glial Cell Line-Derived Neurotrophic Factor

International Journal of Molecular Sciences
Serena StangaPascal Kienlen-Campard
January 16, 2021
Review

Synaptic homeostats: latent plasticity revealed at the Drosophila neuromuscular junction

Cellular and Molecular Life Sciences : CMLS
Pragya Goel, Dion Dickman
January 13, 2021

Myasthenia Gravis and Pregnancy: Toronto Specialty Centre Experience

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
Mohammed AlharbiVera Bril
January 6, 2021

Congenital myasthenic syndrome related to SLC25A1 gene variant: two cases report and literature review

Zhonghua er ke za zhi. Chinese journal of pediatrics
W H LiS Z Zhou
December 31, 2020
Open Access

Light Cross-Linkable Marine Collagen for Coaxial Printing of a 3D Model of Neuromuscular Junction Formation

Biomedicines
Borja SanzGordon Wallace

Sign up to follow this feed and discover related papers.

Related Feeds

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Antisense Oligonucleotide Therapies: ND

Antisense oligonucleotides are synthetic DNA oligomers that hybridize to a target RNA. This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

© 2021 Meta ULC. All rights reserved
/feed-previews/neuromuscular-junction-diseases/96eef402-05f4-49bd-aa1d-7fce351f28d0